推动亚洲感染病临床证据:ADVANCE-ID抗菌药物耐药试验网络
ADVANCE-ID是一个覆盖亚洲100余家医院的临床试验网络,计划扩展至非洲、中东和拉丁美洲。
要点
- 核心目标是产生随机对照试验证据以改善耐药菌感染的治疗、诊断和预防。
- 倡导为中低收入国家争取有证据支持的抗生素和诊断的可及性。
核心结论
- ADVANCE-ID旨在通过高质量临床试验产生全球影响,改善抗菌药物耐药细菌感染的管理。
研究设计与样本
- ADVANCE-ID是一个临床试验网络,涵盖亚洲100余家医院,并计划在非洲、中东和拉丁美洲增设研究站点。
临床怎么用
- 该网络致力于为抗菌药物耐药细菌感染的严重感染提供随机对照试验证据,以优化治疗、诊断和预防策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ADVANCE-ID (ADVancing Clinical Evidence in Infectious Diseases) is a clinical trials network comprising more than 100 hospitals across Asia, with additional research sites planned for Africa, the Middle East, and Latin America. The mission of ADVANCE-ID is to conduct high-quality clinical trials that have a global impact on the management of infection. More than 12 000 patients have been enrolled since 2022 in ADVANCE-ID studies. A key aim of ADVANCE-ID is to create evidence from randomized controlled trials to improve treatment, diagnostics, and prevention strategies of serious infections resulting from antimicrobial-resistant bacterial infections. Alongside this, ADVANCE-ID has a commitment to advocate for access to antibiotics and diagnostics for which evidence exists for their use in low- and middle-income countries.
引用
- Paterson DL. Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the "Antimicrobial Resistance Hot Zone". Clin Infect Dis. 2026. PMID: 42227050. doi:10.1093/cid/ciag122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。